BiomedExperts.com Established As the Gold Standard Supporting Collexis Expert Platforms for Translational Research

COLUMBIA, S.C., April 15 /PRNewswire-FirstCall/ -- Collexis Holdings, Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today that their life science research portal www.BiomedExperts.com has blown past the 145,000 registered user mark and will easily surpass 150,000 by the end of April. The unique visitor traffic in March has exploded to over 60,000 per day and surpassed 1.8 million unique visitors in March!

(Logo: http://www.newscom.com/cgi-bin/prnh/20090107/CLW051LOGO )

"BiomedExperts continues to grow at a very rapid pace and we are highly confident we will go beyond 200,000 registered life science researchers by the fall," stated Bill Kirkland, CEO of Collexis. "Over the next six months we plan to add a number of key features, enhancements and partners to BiomedExperts. Currently, in beta, we are providing our members with weekly alerts of their publications in BiomedExperts as well as new publications within their network. Further this fall, we plan to launch the consumer version of BiomedExperts.com which will allow the global audience to access this life science portal from a healthcare perspective."

"Because the U.S. economic stimulus plan has a significant focus on scientific research, we feel that BiomedExperts will continue to grow as the research community will have an increasing need for effective tools to promote collaboration with other scientists," states Dr. Christian Herzog, M.D., Managing Director for Collexis STM markets. "BiomedExperts is the supporting foundation for all of Collexis' key applications including the Collexis Expert Platform for Translational Research connecting over 30,000 researchers from 43 research organizations, including many grantees of the NIH's Clinical and Translational Science Award (CTSA)."

Pre-populated with over 1.8 million Pub-Med-based expert profiles, BiomedExperts allows scientists and researchers to directly connect with and explore their own professional contacts, grow their networks and identify researchers with the expertise needed for future collaborations. Through user-friendly search interfaces, potential research collaborators can share data and collaborate with professionals from more than 1,800 organizations and institutions from 137 countries, totaling more than 30 million connections made through the site.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio, Cologne, Germany and Valparaiso, Chile. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Disclaimer: National Institutes of Health (NIH) and NIH's CTSA Program are not considered a supporter or partner of Collexis. Reference to NIH or CTSA consortium in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with BiomedExperts.com. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-K for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

SOURCE Collexis Holdings, Inc.